New global data on influenza vaccine provision and level of support for immunization policies

28 November 2011

The findings of two studies being published this week in peer-reviewed journals look at global vaccination policies and use global vaccination provision data that had not been previously available were released yesterday by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

The first study published in Vaccine shows that, despite influenza vaccine provision increasing, levels globally remain low and the rate of growth is slowing. Only 20% countries achieved the study’s conservative threshold which is based on World Health Organization immunization recommendations. Official vaccination recommendations alone do not drive higher coverage; instead public health policies with a direct impact on patients, such as effective communication and reimbursement policies, are associated with higher levels of seasonal influenza vaccination. These factors appeared substantially more important than United Nations development status, which does not appear to correlate directly to coverage levels.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical